Leerink Partners analyst Roanna Ruiz has maintained their bullish stance on LNTH stock, giving a Buy rating on January 23.
Roanna Ruiz has given her Buy rating to Lantheus based on the company’s well-structured CEO succession plan and its strong positioning for future growth. The appointment of Brian Markison as the new CEO is seen as a positive move due to his extensive healthcare experience and his longstanding involvement with Lantheus as a board member. Ruiz believes that this leadership transition, paired with Mary Anne Heino’s continued influence from the board, will provide stability and a “steady hand” to navigate the company through its next phase of development.
Moreover, Ruiz is optimistic about Lantheus’s strategic focus on therapeutic oncology, particularly radioligand therapies, an area where they have core strengths in the radiopharmaceuticals and diagnostics spaces. Despite the setback from the Phase 3 SPLASH trial results, the management’s commitment to no strategic or business disruptions during the transition is seen as reassuring. Investors are expected to closely monitor the new CEO’s vision for the company’s commercial portfolio, which Ruiz anticipates will be outlined in more detail during the upcoming fourth quarter and full-year 2023 earnings announcement.
In another report released on January 23, JMP Securities also reiterated a Buy rating on the stock with a $100.00 price target.
See the top stocks recommended by analysts >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Lantheus (LNTH) Company Description:
Lantheus Holdings, Inc. engages in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its products are used by cardiologists, nuclear physicians, radiologists, internal medicine physicians, sonographers and technologists working in a variety of clinical settings. The firm operates through the following geographical segments: U.S. and International. The U.S. segment produces and markets medical imaging agents and products throughout the U.S. This segment sells its products to radio pharmacies, integrated delivery networks, hospitals, clinics and group practices. The International segment operations consist of production and distribution activities in Puerto Rico and direct distribution activities in Canada. The company was founded in 1956 and is headquartered in North Billerica, MA.
Read More on LNTH:
- Lantheus Announces CEO Retirement and Successor Appointment
- Lantheus Announces CEO Succession Plan
- Lantheus reaffirms 2023 revenue view $1.295B-$1.297B, consensus $1.28B
- Lantheus CEO Mary Anne Heino to retire, Brian Markison to succeed
- Lantheus announces acceptance of its first-to-file ANDA for generic LUTATHERA
